Recent Updates
Recently added Catalysts
BLTE Positive Sentiment Score: 70/100

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Wednesday, February 7, 2024 1 min read
Key Takeaway: Belite Bio, a clinical-stage biopharmaceutical company focused on retinal disease therapeutics, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The presentation is scheduled for February 14 at 12:40 pm ET and will be available via webcast on the company's investor relations page. A replay of the presentation will also be accessible for 90 days after the event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Belite Bio is advancing novel therapeutics for retinal diseases.
  • The company will showcase its work at a prominent healthcare conference.
  • The virtual presentation indicates transparency and engagement with investors.

Full Press Release Details

SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.
A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replay will be archived for 90 days following the presentation date.
Media and Investor Relations Contact:
belite@argotpartners.com

Frequently Asked Questions

When is Belite Bio's presentation at the Oppenheimer conference?

The presentation will occur on February 14, 2024, at 12:40 pm ET.

Where can I watch the Belite Bio presentation?

The webcast will be available on the Belite Bio investor relations website.

How long will the presentation replay be available?

The replay will be archived for 90 days after the presentation.

What is the focus of Belite Bio, Inc.?

Belite Bio focuses on developing therapies for degenerative retinal diseases.

Who can be contacted for media inquiries about Belite Bio?

Media inquiries can be directed to belite@argotpartners.com.

Tags: BLTE Viatris Investor Conferences Healthcare Belite Bio healthcare conference retinal diseases biopharmaceutical
Last updated: Feb 7, 2024